Evommune (EVMN) stock
EVMN's Quality Score rose 1 point on Tue, Oct 6, to -5. Closed near the day's high.
Follow EVMN's trial news. Pro members can get an alert when Evommune files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Holding it back
Moves 10.4% a day with no profit behind it.
4 more reasons behind EVMN's -5, for Pro members
What's next for EVMN, and how long its cash lasts
From Evommune’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts through 2028 (8-K, Jun 29).
Dilution on the horizon
No shelf registration of its own or at-the-market program on file in the last three years.
Insiders
CFO Kyle Carver bought 1,000 shares on Jul 8. 9 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 23 daysINOInovio Pharmaceuticals
INOINO-3107
- In 34 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 46 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why EVMN is down
Down 20.8% over the five sessions to Oct 6 while the S&P 500 rose 1.9%.
It filed an 8-K (items 7.01, 9.01) in those sessions.
−2Volatility moves 10.4% a day on a $95M loss over four quarters, with no positive free cash flow
3 more reasons, the timeline, and the peer table, for Pro members
4 more things pulling EVMN's score down, for Pro members
What's next
Fri Nov 6: One year since its IPOListed Nov 6, 2025 at $16.
Expected to report Mon Nov 16, after the close
After its last 4 reports it closed +1.1% on average, higher 3 of 4 times.
What would turn EVMN's score around: 7 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
EVMN has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1417.9
- MACD (12, 26, 9)Below signal
- 50-day average$11.48
- 200-day average$18.85
- ADX 1446.5
- Resistance$13.35
- Bollinger Bands (20, 2)Inside
- Volume1.0x
How EVMN ranks in Pharma
EVMN is #84 of 92 by Quality Score. The top three are shown with their scores, and more by name.
ABBV10/1421
CRON5/1416
CYRX8/1413
EOLSOpen for its score
ERASOpen for its score
GERNOpen for its score
GMABOpen for its score
EVMN1/14-5
When does EVMN report earnings, and what happens after?
Expected to report Mon Nov 16, after the close (in 40 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026After close | After close | +2.4% | +5.2% | +5.2% |
| May 7, 2026After close | After close | +2.3% | +1.9% | +1.0% |
| Mar 5, 2026After close | After close | -1.0% | +5.6% | -8.4% |
| Dec 11, 2025After close | After close | -2.1% | -8.5% | -23.8% |
Who is trading EVMN
EVMN insider trades
2 insiders bought $146K across 2 filings in the last 6 months. No open-market sales on record. The newest:
About Evommune
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of EVMN's score, with the points and the reason
- All 14 checks on EVMN and on all 3,283 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on EVMN
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.